Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Market Gems:Stocks w/Strong Earnings and High Tech. Rank -- Ignore unavailable to you. Want to Upgrade?

To: Ed Person who wrote (82898)	2/15/2000 2:08:00 AM
From: Jenna	Respond to of 120523

NSATF.. AQLA NSATF no wonder it wasn't on my Israeli mutual fund list. You are right it is Canadian. I thought it went through a transmigration like DOX but its original 100% pure Canadian. AQLA.. moved up on very high volume on Monday. Although most stocks that move up 27% in a day usually don't continue up the next day, but the biotechnology sector is different. Offtimes you can get a company that is caught up in an upward momentum much like CORR, GLGC and ARQL were and the twin earnings plays: MYGN and MEDX. So even if AQLA doesn't move up on Tuesday, it probably will move up after a pullback. "Gamblers" a.k.a daytraders probably will move in on AQLA in the morning but if AQLA is indeed another "CELG" will be proven AFTER the daytraders step into the quicksand first. Lets let the shorters lead the way and test the ground. If they crash and burn, it will be time to get in.. Aquila Biopharmaceuticals Receives License Payments From Partners FRAMINGHAM, Mass., Feb. 14 /PRNewswire/ -- Aquila Biopharmaceuticals, Inc. (Nasdaq: AQLA - news) today announced that it has received milestone payments from two of its corporate partners. One is a payment from Progenics Pharmaceuticals, Inc. in connection with the use of Aquila's lead Stimulon® adjuvant QS-21 in their cancer program. The other payment is from Neuralab Limited, a wholly-owned subsidiary of Elan Corporation, plc (''Elan''), in connection with the use of Aquila's lead Stimulon® adjuvant QS-21 with an undisclosed antigen in the field of Alzheimer's Disease. The Neuralab payment represents the second payment under the license agreement granted in January this year.